Study-related adverse events In a 26-week, open-label study in adult patients (N=665) comparing Victoza 1.2 mg, Victoza 1.8 mg, and sitagliptin 100 mg, all in combination with metformin, the adverse reactions reported in 5% of patients treated with Victoza were nausea (23.9% vs 4.6%), headache (10.3% vs 10.0%), diarrhea (9.3% vs 4.6%), and vomiting (8.7% vs 4.1%)
These tests focus on five key characteristics identity, purity, sterility, endotoxin levels, and heavy metal content ensuring that each product meets the highest standards of quality, with independent third-party Certificates of Analysis (COAs) to verify our commitment to excellence
Skin tightening using medical devices such as Ulthera (ultrasound) or Thermage (radio frequency)
Carnitine and lipoic Acid alleviates protein oxidation in heart mitochondria during aging process
Emerging New Therapies for the Treatment of Type 2 Diabetes Mellitus: Glucagon-like Peptide-1 Receptor Agonists